High MAL2 expression predicts shorter survival in women with triple-negative breast cancer.
Jędrzej BorowczakMarek ZdrenkaWeronika SochaKarol GostomczykKrzysztof SzczerbowskiMateusz ManiewskiHanna AndrusewiczJoanna Łysik-MiśkurkaTomasz NowikiewiczŁukasz SzylbergMagdalena BodnarPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2024)
High MAL2 predicts unfavorable prognosis in triple-negative breast cancer, and its expression is independent of PD-1 levels and clinicopathological features of TNBC.